News | June 07, 2021
Bayer acquires Noria and PSMA Therapeutics
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Aurobindo has one of the most enduring generics ecosystems among peers
India sales grew 23.5% YoY with consolidation of Wockhardt products
Acquisition of A&C expands Aceto’s Western manufacturing footprint
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
